Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it has received approval from China’s National Medical Products Administration (NMPA) to proceed with clinical trials for its innovative tetra-specific antibody, GNC-038. The trials will focus on the treatment of systemic lupus erythematosus and rheumatoid arthritis.
GNC-038: A Pioneering Tetra-Specific Antibody for Autoimmune Diseases
GNC-038 is a groundbreaking tetra-specific antibody that targets CD3, 4-1BB, PD-L1, and CD19. It is the world’s first antibody of its kind to enter clinical development. This drug has already initiated one Phase Ia/Ib study and four Phase Ib/II studies, with indications covering hematological tumors such as acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Expanding GNC-038’s Clinical Reach
The recent approval from the NMPA marks a significant step forward for GNC-038 as it expands its clinical reach into autoimmune diseases. This development highlights the potential versatility of the drug in addressing a broader range of medical conditions, from hematological tumors to autoimmune disorders like systemic lupus erythematosus and rheumatoid arthritis.-Fineline Info & Tech
